InvestSMART

Neurizon Therapeutics Limited (ASX: NUZ) - Announcements

- Current share price for NUZ : $0.087

ASX company news and announcements for Neurizon Therapeutics Limited (NUZ) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Neurizon Therapeutics Limited (NUZ) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Neurizon Therapeutics Limited (NUZ), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Neurizon Therapeutics Limited (NUZ)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$69 Neurizon to Present Latest Results and Key Updates 17 Feb 2025 9:27AM $0.130 $0.087 fallen by 33.08%
$69 FDA Guidance on NUZ-001 IND Application 17 Feb 2025 9:14AM $0.130 $0.087 fallen by 33.08%
$69 Notice of Company Update Webinar 11 Feb 2025 2:29PM $0.138 $0.087 fallen by 36.73%
$69 Change of Director's Interest Notices x3 7 Feb 2025 9:58AM $0.140 $0.087 fallen by 37.86%
$69 US Patent granted for NUZ-001 5 Feb 2025 9:18AM $0.125 $0.087 fallen by 30.40%
$69 Notification regarding unquoted securities - NUZ 31 Jan 2025 4:46PM $0.125 $0.087 fallen by 30.40%
$69 Appendix 4C & Quarterly Update 29 Jan 2025 9:14AM $0.125 $0.087 fallen by 30.40%
$69 Neurizon updates on NUZ-001 IND Application 17 Jan 2025 9:59AM $0.170 $0.087 fallen by 48.82%
$69 Change of Share Registry 16 Jan 2025 8:19AM $0.160 $0.087 fallen by 45.63%
$69 Section 708A Cleansing Statement 27 Dec 2024 5:07PM $0.170 $0.087 fallen by 48.82%
$69 Application for quotation of securities - NUZ 27 Dec 2024 5:00PM $0.170 $0.087 fallen by 48.82%
$69 Neurizon Files IND Application to Support HEALEY ALS Trial 18 Dec 2024 9:13AM $0.175 $0.087 fallen by 50.29%
$69 Neurizon Granted OMPD for NUZ-001 in Europe 17 Dec 2024 8:52AM $0.165 $0.087 fallen by 47.27%
$69 Positive 8-month Interim Data from OLE Study 16 Dec 2024 9:34AM $0.180 $0.087 fallen by 51.67%
$69 Neurizon Presents Company Update and 2025 Outlook 12 Dec 2024 3:08PM $0.185 $0.087 fallen by 52.97%
$69 Neurizon Receives Additional R&D Tax Incentive Rebate 11 Dec 2024 1:47PM $0.170 $0.087 fallen by 48.82%
$69 Notice of Company Update Webinar 5 Dec 2024 9:29AM $0.175 $0.087 fallen by 50.29%
$69 Section 708A Cleansing Statement 29 Nov 2024 4:17PM $0.185 $0.087 fallen by 52.97%
$69 Application for quotation of securities - NUZ 29 Nov 2024 4:06PM $0.185 $0.087 fallen by 52.97%
$69 Updated Securities Trading Policy 19 Nov 2024 12:13PM $0.195 $0.087 fallen by 55.38%
$69 Correction to text positioning error in announcement 15 Nov 2024 6:30PM $0.200 $0.087 fallen by 56.50%
$69 Neurizon Presents Positive Preclinical Data on NUZ-001 15 Nov 2024 9:59AM $0.190 $0.087 fallen by 54.21%
$69 NUZ-001 Reduces Aggregation of Key ALS Disease Target 15 Nov 2024 9:50AM $0.190 $0.087 fallen by 54.21%
$69 Positive opinion received on OMPD for NUZ-001 in Europe 11 Nov 2024 9:39AM $0.190 $0.087 fallen by 54.21%
$69 Change of Director's Interest Notices x4 8 Nov 2024 10:09AM $0.190 $0.087 fallen by 54.21%

151 - 175 of 186 results

Page 7 of 8

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.